Oct 2, 2026 · 3 min · 6 segments
Foghorn Therapeutics and Eli Lilly discontinue their SMARCA2 degrader program, Novartis licenses Abogen's autoimmune mRNA therapy while AstraZeneca, Daiichi Sankyo, and Summit Therapeutics team up on…
Foghorn Therapeutics and Eli Lilly have discontinued development of FHD-909, a first-in-class oral SMARCA 2-to-greater advanced, under the company's 2021 collaboration, after Phase 1 dose escalation data show insufficient anti-tumor activity, despite acceptable tolerability and selective target engagement.
Foghorn Chief Executive Officer Adrian Gottschalk says the SMARCA 2-slash-4 synthetic lethality relationship has not translated into the efficacy needed to advance the program, and the company is cutting 40% of its workforce as it redirects resources toward four proprietary pipeline programs.
Foghorn Therapeutics and Eli Lilly have discontinued development of FHD-909, a first-in-class oral SMARCA 2-to-greater advanced, under the company's 2021 collaboration, after Phase 1 dose escalation data show insufficient anti-tumor activity, despite acceptable tolerability and selective target engagement.
Foghorn Chief Executive Officer Adrian Gottschalk says the SMARCA 2-slash-4 synthetic lethality relationship has not translated into the efficacy needed to advance the program, and the company is cutting 40% of its workforce as it redirects resources toward four proprietary pipeline programs.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.